The phenomenon of ‘non-compliance’ creates a complex lose-lose situation for all parties. Norman Niven, CEO of Protomed explores this in more detail.
Dr. Ingela Herrmann of Next Pharma explains why the outsourcing of OSD manufacturing solves not just a price, flexibility and value proposition, but also overcomes potentially costly GMP and other regulatory considerations.
This article by Dr Thomas Jocks & Dr Dierk Roessner of Wyatt Technology Europe discusses the benefits of new plate reader technology, which has been developed to address the growing need for fast, automated and reliable DLS measurements.
Stephen Mayhew of Kinapse Ltd explores why meaningful early stage valuations require new approaches that integrate complementary evaluation practices to build robust valuation outputs.
The Caribbean region, with a population of approximately 49 million (2009 estimate), offers tremendous research opportunities in certain therapeutic areas. Garth Henry of Caribbean Clinical Trial Services Inc takes you on a tour of this glamorous region.
This article by Graham Hughes of Beta Technology will provide an introduction to the Framework Programme for those in the health, biotechnology and pharmaceutical industries interested in accessing this significant funding stream.
Tassilo Korab of HCPC (Health Care Packaging Council) Europe gives a preview of what to expect at the HCPC Annual Conference, where top experts in healthcare will discuss the benefits of improved patient compliance and how it can contribute to more effective use of medicines and to better outcomes.
Bogdan Comanita and Dave Aycock of Pennakem LLC propose a carbon neutral vision for the future of the chemical industry. This vision prompts for practical steps en route to a zero carbon footprint desiderate, by encouraging the strategic adoption of solvents from renewable resources.
A high percentage of new therapies being announced and discussed in the news currently are based on stem cell products. Products derived from embryonic stem cells and adult cells are now beginning to enter the clinical trial phase of development.